May 10, 2017 | Medical Communications, medical education, rare diseases, recruitment
As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*.
The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death.
Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.”
Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.
“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.”
Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients.
Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU. For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com.
* EvaluatePharma Orphan Drug Report 2015
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
The account management/medical writing paradigm was the cornerstone of medcomms for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's environment requires an integrated,...
The account management/medical writing paradigm was the cornerstone of medcomms for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's environment requires an integrated,...
Yesterday was International Day For The Elimination Of Violence Against Women. It marked the launch of the UNiTE to end the violence against women campaign, which runs for 16 days...
The account management / medical writing paradigm was the cornerstone of medical communications for many years, but evolution in technology, storytelling and an increasingly sophisticated audience has changed this.Instead, today's...
Check out our Lucid Story We are a global healthcare consultancy. We deliver life-transforming value through pioneering solutions that change behaviour, improve clinical practice and advance health outcomes. People are...
Founded in 2007, Lucid Group has grown from a small UK-based medical education agency to a global healthcare consultancy and employs over 400 people with several offices in the UK...
Data analysis is everywhere, and the role it plays in our lives is increasing exponentially. From deciding what car to purchase to what medicine will be prescribed for us, the...
Nick discusses his career journey with Lucid Group and describes what a typical day at Lucid looks like for him.
Professor Andy Black, an experienced board-level executive for the life sciences industry, has joined Lucid Group as non-executive Chairman of the Board.Professor Black, co-founder of Kinapse − an international consultancy to the life...
Q: Welcome to Lucid, Jon! Tell us what you love about recruitmentA: I love being able to play my part in shaping a company’s growth story through the hiring of...
